ReviewInternational journal of antimicrobial agents2023

Nirmatrelvir and COVID-19: development, pharmacokinetics, clinical efficacy, resistance, relapse, and pharmacoeconomics.

Daniele Focosi et al.PubMed ↗Publisher ↗

No numbers read from the abstract.